{"id":"177506","title":"Keyera Announces 2025 Fourth Quarter and Year-End Results","author":null,"feed":"PRTGAM","feedName":"Newswire.ca","published":"Thu Feb 12, 5:00AM CST","image":"N/A","content":"

CALGARY, AB, Feb. 12, 2026 /CNW/ - Keyera Corp. (TSX: KEY) ("Keyera") announced its fourth quarter and year-end financial results today, the highlights of which are included in this news release. To view Management's Discussion and Analysis (the "MD&A") and financial statements, visit either Keyera's website or its filings on SEDAR+ at www.sedarplus.ca.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

","related":[{"id":"740179","title":"Did You Miss These 2026 Medicare Changes?","slug":"did-you-miss-these-2026-medicare-changes","feedName":"Motley Fool","published":"4 minutes ago","categories":[]},{"id":"740080","title":"Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market","slug":"corvus-soquelitinib-trial-completion-adds-a-new-catalyst-in-the-atopic-dermatitis-market","feedName":"Tipranks","published":"13 minutes ago","categories":[]},{"id":"740078","title":"Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors","slug":"edgewise-therapeutics-completes-key-renal-study-for-edg-7500-setting-up-next-steps-for-investors","feedName":"Tipranks","published":"13 minutes ago","categories":[]},{"id":"740076","title":"Novo Nordisk Maps Global Awareness of Metabolic Liver Disease With ACT on MASH Study","slug":"novo-nordisk-maps-global-awareness-of-metabolic-liver-disease-with-act-on-mash-study","feedName":"Tipranks","published":"13 minutes ago","categories":[]},{"id":"740074","title":"Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch","slug":"ocuphires-nyxol-presbyopia-trial-nears-data-what-investors-should-watch","feedName":"Tipranks","published":"13 minutes ago","categories":[]},{"id":"740072","title":"Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst","slug":"viatris-backed-nyxol-trial-completes-phase-3-setting-up-a-key-night-vision-catalyst","feedName":"Tipranks","published":"13 minutes ago","categories":[]},{"id":"740070","title":"Moderna’s Multi-Pathogen mRNA Study Reaches Completion, Supporting a Broader Vaccine Platform","slug":"modernas-multi-pathogen-mrna-study-reaches-completion-supporting-a-broader-vaccine-platform","feedName":"Tipranks","published":"13 minutes ago","categories":[]},{"id":"740103","title":"Bybit Brings Regulators and Global Payment Leaders Together in Georgia to Explore the Future of Crypto Payments","slug":"bybit-brings-regulators-and-global-payment-leaders-together-in-georgia-to-explore-the-future-of-crypto-payments","feedName":"Newswire.ca","published":"13 minutes ago","categories":[]},{"id":"740068","title":"Bavarian Nordic’s Phase 3b Chikungunya Vaccine Trial Sets Up a New Catalyst for BVNRY Investors","slug":"bavarian-nordics-phase-3b-chikungunya-vaccine-trial-sets-up-a-new-catalyst-for-bvnry-investors","feedName":"Tipranks","published":"13 minutes ago","categories":[]}],"sourceId":"newswireca-2026-2-12-keyera-announces-2025-fourth-quarter-and-year-end-results","media":"text","thumbnail":"N/A","canonicalUrl":"https://www.newswire.ca/news-releases/keyera-announces-2025-fourth-quarter-and-year-end-results-827958062.html","feedUrl":null,"slug":"keyera-announces-2025-fourth-quarter-and-year-end-results"}

Latest in

More

Keyera Announces 2025 Fourth Quarter and Year-End Results